Kailos Genetics

What Kailos Genetics does

Kailos Genetics is a Huntsville, Alabama-based clinical genetics company founded in 2010, operating a CAP-accredited and CLIA-certified laboratory on the HudsonAlpha Institute for Biotechnology campus. The company builds genetic testing products on its proprietary TargetRich enrichment technology combined with next-generation DNA sequencing and cloud-based analytics. Its core product portfolio comprises Inspexion (pharmacogenomic testing with 10-day turnaround), Expedio (hereditary cancer risk testing with 15-day turnaround, non-invasive buccal swab collection), and Kailos Prevent / Prevent Plus (preventive health panels aligned to CDC Tier 1 Genomic Applications). The company also sells clinical-grade reagents (Kailos Complete V6 pharmacogenomic panel, Hereditary Cancer V2.5 panel covering 26 genes) and a customizable reagent program (Kailos Flex) to research laboratories.

Kailos operates a direct-pay, no-insurance-billing model, charging flat $200-$250 per genetic screening test, which sidesteps reimbursement cycles and EOBs. Its go-to-market is hybrid: a healthcare-systems and physician partnership program distributing Expedio and Inspexion, direct-to-consumer testing (including the now-ended Information is Power community program serving North Alabama residents), B2B reagent sales to research laboratories, and — following the May 2023 acquisition by healthīme — a new embedded-insurance channel in which Kailos' testing is delivered through healthīme's health navigation platform and Hannover Re US reinsurance to life and critical insurance policyholders.

Since the May 2023 acquisition by healthīme, Kailos has functioned as a wholly-owned subsidiary with founder Brian Pollock serving as President. The company holds registered trademarks for its product brands (TargetRich, Inspexion, Expedio, Kailos Complete, Kailos Flex, ViraWash, ViralPatch, Assure Sentinel) and Medical Director Ron McGlennen, M.D., contributes nine issued and pending patents in molecular biology and genetics. Service is available throughout the U.S. with the exception of New York. Headcount is in the 11-50 range, and no institutional venture funding rounds have been disclosed beyond a 2011 round and a 2017 In-Q-Tel (IQT) investment.

Name

Kailos Genetics

Legal name

Kailos Genetics, LLC

Website

https://kailosgenetics.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Kailos Genetics is a CAP-accredited, CLIA-certified clinical genetics laboratory in Huntsville, Alabama, offering pharmacogenomic (Inspexion), hereditary cancer (Expedio), and preventive health (Kailos Prevent) testing built on proprietary TargetRich enrichment and NGS, serving healthcare systems, consumers, research labs, and now insurance policyholders via its healthīme parent.

Ownership category

akta.pro rank

Product category

Clinical Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

Keywords

• Clinical genetic testing
• Pharmacogenomic testing
• Hereditary cancer testing
• Next-generation sequencing
• Precision medicine services

Headquarters

HQ city

Huntsville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Clinical genetic testing services: Direct-pay genetic testing services including hereditary cancer risk testing and pharmacogenetic testing, billed at contracted flat rates without insurance claims.
2. Laboratory reagent sales: Sale of clinical grade laboratory reagents and reagents for next-generation sequencing to research laboratories. Includes assay design services, validated protocols, and cloud-based analytic software solutions.
3. COVID-19 surveillance testing: Workplace viral suppression programs using Assure Sentinel testing for organizations, schools, and healthcare partners.
4. Enterprise laboratory services: Full range of laboratory services to healthŌme and other healthcare/life insurance partners, diversified beyond traditional healthcare reimbursement systems.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Kailos Genetics operates a CAP-accredited, CLIA-certified clinical laboratory providing precision medicine genetic testing services, including hereditary cancer risk testing (Expedio) and pharmacogenomic testing (Inspexion), using proprietary TargetRich enrichment technology and next-generation DNA sequencing. The company also sells clinical-grade next-generation sequencing reagents and offers customizable panel design (Kailos Flex) to research laboratories, with HIPAA-compliant cloud-based analytics and data delivery integration.

Product overview

Kailos Genetics offers a precision medicine platform built around proprietary TargetRich™ enrichment technology and next-generation DNA sequencing. The core product portfolio centers on three main testing services: Inspexion™ for pharmacogenomic testing (identifying genetic variations affecting medication metabolism), Expedio™ for hereditary cancer risk testing, and Kailos Prevent™ for high-prevalence actionable health conditions. The company also provides clinical-grade laboratory reagents through its Kailos Complete™ V6 and V2.5 panels, and offers customization through its Kailos Flex™ program. All laboratory services are delivered through a CAP-accredited, CLIA-certified facility at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama.

Differentiator

Problem solved

Functional benefit

Brands

• Inspexion: Pharmacogenomic testing service using next-generation DNA sequencing
• Expedio
• Kailos Prevent
• Assure Sentinel
• Kailos Complete
• Kailos Flex
• ViraWash
• ViralPatch

Products and services

• Inspexion Pharmacogenomic Testing Comprehensive pharmacogenetic testing service using next-generation DNA sequencing to identify genetic variations affecting medication metabolism. Provides metabolic information for key pharmacogenes with 10-day turnaround time and multiple reporting options. Designed for physicians and patients seeking to understand how genetic variations affect drug response.
• Expedio Hereditary Cancer Risk Testing Hereditary cancer mutation testing service using next-generation DNA sequencing with non-invasive buccal swab sample collection. Results delivered within 15 days with comprehensive consultations for genotypes and reported results. Designed for physicians and patients seeking hereditary cancer risk assessment.
• Kailos Prevent Genetic testing service for high-prevalence actionable conditions including cancer, heart disease, strokes, and metabolism of antidepressants and opioids. Designed around CDC Tier 1 Genomic Applications guidelines for identifying DNA changes with significant potential for positive health impact.
• Assure Sentinel COVID-19 Workplace Surveillance Testing COVID-19 workplace surveillance testing program using ViraWash non-invasive saliva-based sample collection and ViralPatch proprietary viral capture and sample pooling methodology combined with next-generation DNA sequencing. Designed for employers, non-profit organizations, and schools seeking cost-efficient testing to enable safe operations.
• Kailos Complete V6 Pharmacogenomic Panel Clinical grade next-generation sequencing reagent panel targeting pharmacogenes for pharmacogenomic testing. Sold to research laboratories as part of Kailos's complete sequencing solution that includes assay design, validated protocols, and cloud-based analytic software.
• Kailos Complete Hereditary Cancer V2.5 Panel Clinical grade next-generation sequencing reagents for hereditary cancer testing targeting 26 genes. Available as a Research Use Only (RUO) product for laboratory reagent programs, sold to research laboratories with cloud-based analytics.
• Kailos Flex Customizable Reagent Program Customizable laboratory reagent program allowing research laboratories to specify particular gene targets for their research applications. Includes cloud-based analytics software with HIPAA-compliant secure data delivery. Provides full sequencing solution from assay design to data analysis.

Quantifiable outcome

• Over 7,000 participants served through Information is Power program
• +2 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Four partnerships are on record, tiered core and minor.

• University of Minnesota College of PharmacycoreStrategic or Co-development Partner · 1 February 2021Established pharmacogenetic testing and internship program offering Kailos Genetics' Inspexion pharmacogenetic testing service to first year pharmacy students. Through an application process, internships with Kailos Genetics are offered to University of Minnesota students focused on the utility of pharmacogenetics in healthcare. This partnership supports education and technology in genetics and pharmacy to improve patient health outcomes.
• HH Health System (Huntsville Hospital Health System)coreChannel Partner/ Reseller/ Distributor · 21 October 2020Partnership to offer COVID-19 surveillance testing through Assure Sentinel program. HH Health System offers the service through its Corporate Wellness, Occupational Health Group, and HH Health System Reference Laboratory Network. HH Health System staff administers tests, collects samples, and communicates results to tested individuals and employers.
• Huntingdon CollegeminorChannel Partner/ Reseller/ Distributor · 1 October 2020COVID-19 testing partnership for campus reopening. Huntingdon College identified access to testing as a key element to responsibly reopen campus. Kailos provided a reasonably priced, efficient testing option critical in mitigating COVID-19 spread on campus.
• HudsonAlpha Institute for BiotechnologycoreStrategic or Co-development Partner · 1 January 2010Kailos Genetics is a resident company at the HudsonAlpha Institute for Biotechnology campus. Founded in 2010 and located at HudsonAlpha, Kailos is one of over 40 associate companies on the 152-acre campus. The Institute and its associated companies have had a $2.45 billion impact on the Alabama state economy. Jim Hudson, a founder of HudsonAlpha, noted the strategic fit of bringing together two HudsonAlpha associate companies.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• OneOme: OneOme specializes in pharmacogenomic testing with partner-driven distribution to hospitals and clinicians, mirroring Kailos' Inspexion PGx panel, health system partnership channel, and physician-directed positioning.
• Natera: Natera runs a CAP/CLIA-accredited molecular diagnostics lab focused on hereditary cancer screening, reproductive health, and oncology NGS — overlapping with Kailos' hereditary cancer and broader NGS-based testing portfolio.
• Ambry Genetics: Ambry (now part of Labcorp) is a CAP/CLIA-accredited specialty lab offering hereditary cancer and multi-gene NGS panels plus customizable assays — the closest large-scale analog to Kailos' clinical lab and Kailos Complete reagent model.
• Color Health: Color offers hereditary cancer, pharmacogenomics, and population health genetic testing at comparable price points ($249) with employer and health system partnerships — directly overlapping Kailos' Inspexion, Expedio, and channel motion.
• Fulgent Genetics: Fulgent offers NGS-based hereditary cancer, pharmacogenomics, and customizable clinical panels with health system partnerships — comparable to Kailos' Kailos Complete and Kailos Flex reagent/program offerings.
• GeneDx: GeneDx operates a CLIA-certified clinical lab delivering hereditary cancer, rare disease, and pharmacogenomic NGS testing with health system partnerships — directly comparable to Kailos on test menu, regulatory posture, and B2B go-to-market.

Broad incumbents

• Labcorp: Labcorp operates extensive clinical lab capacity and, through its ownership of Ambry Genetics, competes directly in hereditary cancer NGS testing, making it a broad incumbent analog to Kailos' clinical services.
• Quest Diagnostics: Quest is a large national reference lab providing genetic and molecular diagnostics including hereditary cancer screening — overlapping as a broad incumbent competitor for physician-ordered testing volume.
• 23andMe: 23andMe pioneered the direct-to-consumer genetic testing model that Kailos' Information is Power program emulated; as a broader incumbent in DTC and B2B genomics, it represents a competitive reference point on consumer channel and pricing.
• Myriad Genetics: Myriad is an established molecular diagnostics leader with a hereditary cancer franchise plus broader oncology and pharmacogenomics offerings, making it a broader incumbent peer in the same clinical genomics category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/kailosgenetics
• Facebookfacebook.com/kailostest
• LinkedInlinkedin.com/company/1283848

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kailos Genetics